| Titre |
A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours |
| Protocole ID |
TROPION-PanTumor03 |
| ClinicalTrials.gov ID |
NCT05489211 |
| Type(s) de cancer |
Tumeurs solides |
| Phase |
Phase II |
| Stade |
Maladie avancée ou métastatique |
| Type étude |
Clinique |
| Médicament |
Datopotamab deruxtecan en monothérapie et en association avec des agents anticancéreux |
| Institution |
CHU DE QUEBEC – UNIVERSITE LAVAL
 HOPITAL DE L'ENFANT-JESUS
1401 18e Rue, Québec, QC, G1J 1Z4
|
| Ville |
Québec |
| Investigateur(trice) principal(e) |
Dr Vincent Castonguay
|
| Coordonnateur(trice) |
Philippe Nadeau
418-649-0252 poste 63115
|
| Statut |
 Actif en recrutement |
| Date d'activation |
18-10-2023 |
| Critètes d'éligibilité |
- Male and female, ≥ 18 years
- Histologically or cytologically documented advanced or metastatic malignancy.
- At least 1 lesion not previously irradiated that qualifies as a RECIST 1.1 target lesion at baseline Substudy 3 (mCRPC) allows enrolment of participants with non measurable (by RECIST 1.1) bone metastatic disease.
- Adequate bone marrow reserve and organ function within 7 days before randomization/treatment
- Minimum life expectancy of 12 weeks
|
| Critètes d'exclusion |
- Persistent toxicities caused by previous anticancer therapy, excluding alopecia, not yet improved to Grade ≤ 1 or baseline
- Spinal cord compression or brain metastases unless treated
- Leptomeningeal carcinomatosis
- Clinically significant corneal disease
- Active hepatitis or uncontrolled hepatitis B or C virus infection
- Uncontrolled infection requiring IV antibiotics, antivirals or antifungals eg, prodromal symptoms
- Significant cardiac diseases
- History of non-infectious Interstitial lung disease (ILD)/pneumonitis that required steroids
- Prior exposure to chloroquine/hydroxychloroquine without an adequate treatment washout period
- Prior exposure to anticancer therapies without an adequate treatment washout period prior to enrolment
- Prior treatment with TROP2-directed Anti-drug antibody ADC Antibody-drug conjugate (ADCs), other ADCs with deruxtecan payload
- Severe hypersensitivity to Dato-DXd monoclonal antibodies polysorbate 80 or other monoclonal antibodies.
- Pregnant, breastfeeding, planning to become pregnant.
|
Groupe d'étude en oncologie du Québec